Tuesday, August 15 2006 11:19 Hrs (IST) - World Time -

New Delhi: Country's largest drug maker, Ranbaxy Laboratories Limited (RLL) yesterday (Aug 14, 2006) said it had received approval to manufacture and market anti-AIDS/HIV drug for children 'Triviro-LNS kid' and 'Triviro-LNS kid DS' in India and also filed with WHO Geneva for pre-qualification for the same.

Both the products are triple anti-retroviral (ARV) combinations for children. While Triviro-LNS kid contains Lamivudine 20mg, Nevirapine 35mg, and Stavudine 5mg, Triviro-LNS kid DS contains the drugs in 40mg, 70mg and 10mg strengths respectively, the company said in a statement.

"We hope that with these new formulations, we will be able to make accessible, a high quality and convenient treatment to a large number of HIV-positive children who are presently among the therapeutically most neglected, RLL CEO and Managing Director Malvinder Mohan Singh said.

The products are bio-equivalent with the individual liquid formulations of the originators. The products are indicated for treatment of HIV infection in children, the statement added.